Pharmaceuticals BRIC (Brazil, Russia, India, China) Industry Guide 2013-2022
June 2018
113
About the Report
About the Report
Pharmaceuticals BRIC (Brazil, Russia, India, China) Industry Guide 2013-2022
Summary
The BRIC Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Synopsis
Essential resource for top-line data and analysis covering the BRIC pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.
Key Highlights
- Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the pharmaceuticals industry and had a total market value of USD 192.3 billion in 2017. India was the fastest growing country with a CAGR of 15.9% over the 2013-17 period.
- Within the pharmaceuticals industry, China is the leading country among the BRIC nations with market revenues of USD 108.3 billion in 2017. This was followed by India, Brazil and Russia with a value of USD 35.2, USD 26.1, and USD 22.7 billion, respectively.
- China is expected to lead the pharmaceuticals industry in the BRIC nations with a value of USD 173.1 billion in 2022, followed by India, Russia, Brazil with expected values of USD 70.2, USD 41.3 and USD 31.0 billion, respectively.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the BRIC pharmaceuticals market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the BRIC pharmaceuticals market
- Leading company profiles reveal details of key pharmaceuticals market players' BRIC operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the BRIC pharmaceuticals market with five year forecasts
- Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country
Reasons to buy
- What was the size of the BRIC pharmaceuticals market by value in 2017?
- What will be the size of the BRIC pharmaceuticals market in 2022?
- What factors are affecting the strength of competition in the BRIC pharmaceuticals market?
- How has the market performed over the last five years?
- Who are the top competitors in the BRIC pharmaceuticals market?
Products
Companies
Table of Contents
Table of Contents
Table of Contents
BRIC Pharmaceuticals 10
Industry Outlook 10
Introduction 13
What is this report about? 13
Who is the target reader? 13
How to use this report 13
Definitions 13
Pharmaceuticals in Brazil 14
Market Overview 14
Market Data 15
Market Segmentation 16
Market outlook 18
Five forces analysis 19
Pharmaceuticals in China 27
Market Overview 27
Market Data 28
Market Segmentation 29
Market outlook 31
Five forces analysis 32
Macroeconomic indicators 41
Macroeconomic indicators 43
Pharmaceuticals in India 45
Market Overview 45
Market Data 46
Market Segmentation 47
Market outlook 49
Five forces analysis 50
Macroeconomic indicators 59
Pharmaceuticals in Russia 61
Market Overview 61
Market Data 62
Market Segmentation 63
Market outlook 65
Five forces analysis 66
Macroeconomic indicators 76
Company Profiles 78
Leading Companies 78
Appendix 111
Methodology 111
About MarketLine 112
List of Figure
List of Figures
Figure 1: BRIC pharmaceuticals industry, revenue(USD bn), 2013-22
Figure 2: BRIC pharmaceuticals industry, revenue(USD bn), 2013-17
Figure 3: BRIC pharmaceuticals industry, revenue(USD bn), 2017-22
Figure 4: Brazil pharmaceuticals market value: USD billion, 2013-17
Figure 5: Brazil pharmaceuticals market geography segmentation: % share, by value, 2017
Figure 6: Brazil pharmaceuticals market share: % share, by value, 2017
Figure 7: Brazil pharmaceuticals market value forecast: USD billion, 2017-22
Figure 8: Forces driving competition in the pharmaceuticals market in Brazil, 2017
Figure 9: Drivers of buyer power in the pharmaceuticals market in Brazil, 2017
Figure 10: Drivers of supplier power in the pharmaceuticals market in Brazil, 2017
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Brazil, 2017
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Brazil, 2017
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Brazil, 2017
Figure 14: China pharmaceuticals market value: USD billion, 2013-17
Figure 15: China pharmaceuticals market geography segmentation: % share, by value, 2017
Figure 16: China pharmaceuticals market share: % share, by value, 2017
Figure 17: China pharmaceuticals market value forecast: USD billion, 2017-22
Figure 18: Forces driving competition in the pharmaceuticals market in China, 2017
Figure 19: Drivers of buyer power in the pharmaceuticals market in China, 2017
Figure 20: Drivers of supplier power in the pharmaceuticals market in China, 2017
Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in China, 2017
Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in China, 2017
Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in China, 2017
Figure 24: India pharmaceuticals market value: USD billion, 2013-17
Figure 25: India pharmaceuticals market geography segmentation: % share, by value, 2017
Figure 26: India pharmaceuticals market share: % share, by value, 2017
Figure 27: India pharmaceuticals market value forecast: USD billion, 2017-22
Figure 28: Forces driving competition in the pharmaceuticals market in India, 2017
Figure 29: Drivers of buyer power in the pharmaceuticals market in India, 2017
Figure 30: Drivers of supplier power in the pharmaceuticals market in India, 2017
Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in India, 2017
Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in India, 2017
Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in India, 2017
Figure 34: Russia pharmaceuticals market value: USD billion, 2013-17
Figure 35: Russia pharmaceuticals market geography segmentation: % share, by value, 2017
Figure 36: Russia pharmaceuticals market share: % share, by value, 2017
Figure 37: Russia pharmaceuticals market value forecast: USD billion, 2017-22
Figure 38: Forces driving competition in the pharmaceuticals market in Russia, 2017
Figure 39: Drivers of buyer power in the pharmaceuticals market in Russia, 2017
Figure 40: Drivers of supplier power in the pharmaceuticals market in Russia, 2017
Figure 41: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Russia, 2017
Figure 42: Factors influencing the threat of substitutes in the pharmaceuticals market in Russia, 2017
Figure 43: Drivers of degree of rivalry in the pharmaceuticals market in Russia, 2017
Figure 44: Shanghai Pharmaceutical Co Ltd: revenues & profitability
Figure 45: Shanghai Pharmaceutical Co Ltd: assets & liabilities
Figure 46: Yunnan Baiyao Group Co Ltd: revenues & profitability
Figure 47: Yunnan Baiyao Group Co Ltd: assets & liabilities
Figure 48: Aurobindo Pharma Limited: revenues & profitability
Figure 49: Aurobindo Pharma Limited: assets & liabilities
Figure 50: Dr. Reddy's Laboratories Limited: revenues & profitability
Figure 51: Dr. Reddy's Laboratories Limited: assets & liabilities
Figure 52: Lupin Limited: revenues & profitability
Figure 53: Lupin Limited: assets & liabilities
Figure 54: Sun Pharmaceutical Industries Limited: revenues & profitability
Figure 55: Sun Pharmaceutical Industries Limited: assets & liabilities
Figure 56: Bayer AG: revenues & profitability
Figure 57: Bayer AG: assets & liabilities
Figure 58: Novartis AG: revenues & profitability
Figure 59: Novartis AG: assets & liabilities
Figure 60: Sanofi SA: revenues & profitability
Figure 61: Sanofi SA: assets & liabilities
List of Table
List of Tables
Table 1: BRIC pharmaceuticals industry, revenue(USD bn), 2013-22
Table 2: BRIC pharmaceuticals industry, revenue(USD bn), 2013-17
Table 3: BRIC pharmaceuticals industry, revenue(USD bn), 2017-22
Table 4: Brazil pharmaceuticals market value: USD billion, 2013-17
Table 5: Brazil pharmaceuticals market geography segmentation: USD billion, 2017
Table 6: Brazil pharmaceuticals market share: % share, by value, 2017
Table 7: Brazil pharmaceuticals market value forecast: USD billion, 2017-22
Table 8: China pharmaceuticals market value: USD billion, 2013-17
Table 9: China pharmaceuticals market geography segmentation: USD billion, 2017
Table 10: China pharmaceuticals market share: % share, by value, 2017
Table 11: China pharmaceuticals market value forecast: USD billion, 2017-22
Table 12: China size of population (million), 2013-17
Table 13: China gdp (constant 2005 prices, USD billion), 2013-17
Table 14: China gdp (current prices, USD billion), 2013-17
Table 15: China inflation, 2013-17
Table 16: China consumer price index (absolute), 2013-17
Table 17: China exchange rate, 2013-17
Table 18: Brazil size of population (million), 2013-17
Table 19: Brazil gdp (constant 2005 prices, USD billion), 2013-17
Table 20: Brazil gdp (current prices, USD billion), 2013-17
Table 21: Brazil inflation, 2013-17
Table 22: Brazil consumer price index (absolute), 2013-17
Table 23: Brazil exchange rate, 2013-17
Table 24: India pharmaceuticals market value: USD billion, 2013-17
Table 25: India pharmaceuticals market geography segmentation: USD billion, 2017
Table 26: India pharmaceuticals market share: % share, by value, 2017
Table 27: India pharmaceuticals market value forecast: USD billion, 2017-22
Table 28: India size of population (million), 2013-17
Table 29: India gdp (constant 2005 prices, USD billion), 2013-17
Table 30: India gdp (current prices, USD billion), 2013-17
Table 31: India inflation, 2013-17
Table 32: India consumer price index (absolute), 2013-17
Table 33: India exchange rate, 2013-17
Table 34: Russia pharmaceuticals market value: USD billion, 2013-17
Table 35: Russia pharmaceuticals market geography segmentation: USD billion, 2017
Table 36: Russia pharmaceuticals market share: % share, by value, 2017
Table 37: Russia pharmaceuticals market value forecast: USD billion, 2017-22
Table 38: Russia size of population (million), 2013-17
Table 39: Russia gdp (constant 2005 prices, USD billion), 2013-17
Table 40: Russia gdp (current prices, USD billion), 2013-17
Table 41: Russia inflation, 2013-17
Table 42: Russia consumer price index (absolute), 2013-17
Table 43: Russia exchange rate, 2013-17
Table 44: Ache Laboratorios Farmaceuticos S.A.: key facts
Table 45: EMS Sigma Pharma: key facts
Table 46: Guangzhou Pharmaceutical Holdings Limited: key facts
Table 47: Shanghai Pharmaceutical Co Ltd: key facts
Table 48: Shanghai Pharmaceutical Co Ltd: key financials (USD )
Table 49: Shanghai Pharmaceutical Co Ltd: key financials (CNY)
Table 50: Shanghai Pharmaceutical Co Ltd: key financial ratios
Table 51: Yangtze River Pharmaceutical Group: key facts
Table 52: Yunnan Baiyao Group Co Ltd: key facts
Table 53: Yunnan Baiyao Group Co Ltd: key financials (USD )
Table 54: Yunnan Baiyao Group Co Ltd: key financials (CNY)
Table 55: Yunnan Baiyao Group Co Ltd: key financial ratios
Table 56: Aurobindo Pharma Limited: key facts
Table 57: Aurobindo Pharma Limited: key financials (USD )
Table 58: Aurobindo Pharma Limited: key financials (AUSD )
Table 59: Aurobindo Pharma Limited: key financial ratios
Table 60: Dr. Reddy's Laboratories Limited: key facts
Table 61: Dr. Reddy's Laboratories Limited: key financials (USD )
Table 62: Dr. Reddy's Laboratories Limited: key financials (Rs.)
Table 63: Dr. Reddy's Laboratories Limited: key financial ratios
Table 64: Lupin Limited: key facts
Table 65: Lupin Limited: key financials (USD )
Table 66: Lupin Limited: key financials (Rs.)
Table 67: Lupin Limited: key financial ratios
Table 68: Sun Pharmaceutical Industries Limited: key facts
Table 69: Sun Pharmaceutical Industries Limited: key financials (USD )
Table 70: Sun Pharmaceutical Industries Limited: key financials (Rs.)
Table 71: Sun Pharmaceutical Industries Limited: key financial ratios
Table 72: Bayer AG: key facts
Table 73: Bayer AG: key financials (USD )
Table 74: Bayer AG: key financials (EUR)
Table 75: Bayer AG: key financial ratios
Table 76: Les Laboratoires Servier: key facts
Table 77: Novartis AG: key facts
Table 78: Novartis AG: key financials (USD )
Table 79: Novartis AG: key financial ratios
Table 80: Sanofi SA: key facts
Table 81: Sanofi SA: key financials (USD )
Table 82: Sanofi SA: key financials (EUR)
Table 83: Sanofi SA: key financial ratios
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.